{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:50:20Z","timestamp":1787838620289,"version":"build-2784847793"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,18]],"date-time":"2021-12-18T00:00:00Z","timestamp":1639785600000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The East Central (EC) region of Uganda has the least viral suppression rate despite having a relatively low prevalence of human immunodeficiency virus (HIV). Although the viral suppression rate in Kamuli district is higher than that observed in some of the districts in the region, the district has one of the largest populations of people living with HIV (PLHIV). We sought to examine the factors associated with viral suppression after the provision of intensive adherence counselling (IAC) among PLHIV in the district.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We reviewed records of PLHIV and used them to construct a retrospective cohort of patients that started and completed IAC during January \u2013 December 2019 at three high volume HIV treatment facilities in Kamuli district. We also conducted key informant interviews of focal persons at the study sites. We summarized the data descriptively, tested differences in the outcome (viral suppression after IAC) using chi-square and t-tests, and established independently associated factors using log-binomial regression analysis with robust standard errors at 5% statistical significance level using STATA version 15.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We reviewed 283 records of PLHIV. The mean age of the participants was 35.06 (SD 18.36) years. The majority of the participants were female (56.89%, 161\/283). The viral suppression rate after IAC was 74.20% (210\/283). The most frequent barriers to ART adherence reported were forgetfulness 166 (58.66%) and changes in the daily routine 130 (45.94). At multivariable analysis, participants that had a pre-IAC viral load that was greater than 2000 copies\/ml [adjusted Prevalence Risk Ratio (aPRR)= 0.81 (0.70 - 0.93), p=0.002] and those that had a previous history of viral load un-suppression [aPRR= 0.79 (0.66 - 0.94), p=0.007] were less likely to achieve a suppressed viral load after IAC. ART\u00a0drug shortages were rare, ART clinic working hours were convenient for clients\u00a0and\u00a0ART clinic staff received training in IAC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Despite the consistency in drug availability, counselling training, flexible and frequent ART clinic days, the viral suppression rate after IAC did not meet recommended targets. A high viral load before IAC and a viral rebound were independently associated with having an unsuppressed viral load after IAC. IAC alone may not be enough to achieve viral suppression among PLHIV. To improve viral suppression rates after IAC, other complementary services\u00a0should be paired with IAC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12889-021-12366-4","type":"journal-article","created":{"date-parts":[[2021,12,18]],"date-time":"2021-12-18T00:02:28Z","timestamp":1639785748000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Unsuppressed viral load after intensive adherence counselling in rural eastern Uganda; a case of Kamuli district, Uganda"],"prefix":"10.1186","volume":"21","author":[{"given":"Geoffrey","family":"Ndikabona","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Bosco","family":"Alege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas Sebuliba","family":"Kirirabwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derrick","family":"Kimuli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,18]]},"reference":[{"key":"12366_CR1","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1186\/s12889-018-5964-x","volume":"18","author":"E Nasuuna","year":"2018","unstructured":"Nasuuna E, et al. Low HIV viral suppression rates following the intensive adherence counseling (IAC) program for children and adolescents with viral failure in public health facilities in Uganda. BMC Public Health. 2018;18:1048.","journal-title":"BMC Public Health"},{"key":"12366_CR2","doi-asserted-by":"publisher","first-page":"S213","DOI":"10.1097\/QAD.0000000000002355","volume":"33","author":"K Marsh","year":"2019","unstructured":"Marsh K, et al. Global, regional and country-level 90\u201390\u201390 estimates for 2018: assessing progress towards the 2020 target. AIDS. 2019;33:S213.","journal-title":"AIDS"},{"key":"12366_CR3","unstructured":"WHO | HIV\/AIDS. WHO http:\/\/www.who.int\/gho\/hiv\/en\/ (2019)."},{"key":"12366_CR4","doi-asserted-by":"crossref","unstructured":"Maina EK, et al. Incidences and factors associated with viral suppression or rebound among HIV patients on combination antiretroviral therapy from three counties in Kenya. Int. J. Infect. Dis. 2020;97:151\u20138.","DOI":"10.1016\/j.ijid.2020.05.097"},{"key":"12366_CR5","doi-asserted-by":"crossref","unstructured":"Diress G, Dagne S, Alemnew B, Adane S, Addisu A. Viral Load Suppression after Enhanced Adherence Counseling and Its Predictors among High Viral Load HIV Seropositive People in North Wollo Zone Public Hospitals, Northeast Ethiopia, 2019: Retrospective Cohort Study. AIDS Res. Treat. 2020;2020:e8909232.","DOI":"10.1155\/2020\/8909232"},{"key":"12366_CR6","doi-asserted-by":"crossref","unstructured":"Tanner Z, et al. Predictors of viral suppression and rebound among HIV-positive men who have sex with men in a large multi-site Canadian cohort. BMC Infect. Dis. 2016;16:590.","DOI":"10.1186\/s12879-016-1926-z"},{"key":"12366_CR7","doi-asserted-by":"crossref","unstructured":"Korobchuk A, et al. People with high HIV viral load within risk networks: who are these people and who refers them best? J. Infect. Dev. Ctries. 2019;13:103S\u201310S.","DOI":"10.3855\/jidc.11273"},{"key":"12366_CR8","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1097\/QAD.0b013e32832b7dca","volume":"23","author":"S Attia","year":"2009","unstructured":"Attia S, Egger M, M\u00fcller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS. 2009;23:1397\u2013404.","journal-title":"AIDS"},{"key":"12366_CR9","doi-asserted-by":"crossref","unstructured":"Coll O, et al. Vertical HIV-1 transmission correlates with a high maternal viral load at delivery. J. Acquir. Immune Defic. Syndr. Hum. Retrovirology Off. Publ. Int. Retrovirology Assoc. 1997;14:26\u201330.","DOI":"10.1097\/00042560-199701010-00005"},{"key":"12366_CR10","doi-asserted-by":"crossref","unstructured":"Fox MP, et al. Delays in repeat HIV viral load testing for those with elevated viral loads: a national perspective from South Africa. J. Int. AIDS Soc. 2020;23:e25542.","DOI":"10.1002\/jia2.25542"},{"key":"12366_CR11","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1001\/jama.2018.21167","volume":"321","author":"RW Eisinger","year":"2019","unstructured":"Eisinger RW, Dieffenbach CW, Fauci AS. HIV Viral Load and Transmissibility of HIV Infection: Undetectable Equals Untransmittable. JAMA. 2019;321:451.","journal-title":"JAMA"},{"key":"12366_CR12","unstructured":"Beyrer, C. Consolidated Guidelines on Hiv Prevention, Diagnosis, Treatment and Care for Key Populations. (World Health Organization, 2016)."},{"key":"12366_CR13","doi-asserted-by":"crossref","unstructured":"Nakalega R, et al. Linkage to intensive adherence counselling among HIV-positive persons on ART with detectable viral load in Gomba district, rural Uganda. AIDS Res. Ther. 2021;18:15.","DOI":"10.1186\/s12981-021-00349-9"},{"key":"12366_CR14","unstructured":"WHO, W. H. O. HIV Treatment and Care: WHO HIV Policy Adoption and Implementation Status in Countries. (2018)."},{"key":"12366_CR15","doi-asserted-by":"crossref","unstructured":"Rangarajan S, et al. Factors associated with HIV viral load suppression on antiretroviral therapy in Vietnam. J. Virus Erad. 2016;2:94\u2013101.","DOI":"10.1016\/S2055-6640(20)30466-0"},{"key":"12366_CR16","unstructured":"Engsig FN, et al. Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery. Clin. Infect. Dis. 2014;58:1312\u201321."},{"key":"12366_CR17","doi-asserted-by":"crossref","unstructured":"Cohen MS, et al. Prevention of HIV-1 Infection with Early Antiretroviral Therapy. N. Engl. J. Med. 2011;365:493\u2013505.","DOI":"10.1056\/NEJMc1110588"},{"key":"12366_CR18","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1080\/09540121.2013.855699","volume":"26","author":"G Fatti","year":"2014","unstructured":"Fatti G, Shaikh N, Eley B, Grimwood A. Improved virological suppression in children on antiretroviral treatment receiving community-based adherence support: A multicentre cohort study from South Africa. AIDS Care. 2014;26:448\u201353.","journal-title":"AIDS Care"},{"key":"12366_CR19","doi-asserted-by":"publisher","first-page":"e100273","DOI":"10.1371\/journal.pone.0100273","volume":"9","author":"G Fatti","year":"2014","unstructured":"Fatti G, Mothibi E, Meintjes G, Grimwood A. Antiretroviral Treatment Outcomes amongst Older Adults in a Large Multicentre Cohort in South Africa. PLoS ONE. 2014;9:e100273.","journal-title":"PLoS ONE"},{"key":"12366_CR20","unstructured":"Ministry of Health. Consolidated guidelines for the prevention and treatment of HIV and AIDS in Uganda. (2018)."},{"key":"12366_CR21","unstructured":"UBOS and ICF, U. B. of S. Uganda Demographic and Health Survey 2016. (2018)."},{"key":"12366_CR22","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1001\/jama.279.1.35","volume":"279","author":"D Vlahov","year":"1998","unstructured":"Vlahov D, et al. Prognostic Indicators for AIDS and Infectious Disease Death in HIV-Infected Injection Drug Users: Plasma Viral Load and CD4 + Cell Count. JAMA. 1998;279:35.","journal-title":"JAMA"},{"key":"12366_CR23","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/j.1750-3639.1998.tb00153.x","volume":"8","author":"CA Wiley","year":"2006","unstructured":"Wiley CA, et al. Distribution of Brain HIV Load in AIDS. Brain Pathol. 2006;8:277\u201384.","journal-title":"Brain Pathol."},{"key":"12366_CR24","doi-asserted-by":"crossref","unstructured":"Van Dyke RB, et al. Reported Adherence as a Determinant of Response to Highly Active Antiretroviral Therapy in Children Who Have Human Immunodeficiency Virus Infection. PEDIATRICS. 2002;109:e61\u20131.","DOI":"10.1542\/peds.109.4.e61"},{"key":"12366_CR25","doi-asserted-by":"crossref","unstructured":"Murphy RA, et al. Outcomes After Virologic Failure of First-line ART in South Africa. AIDS Lond. Engl. 2010;24:1007\u201312.","DOI":"10.1097\/QAD.0b013e3283333639"},{"key":"12366_CR26","doi-asserted-by":"crossref","unstructured":"Kim MJ, et al. Comparison of Antiretroviral Regimens: Adverse Effects and Tolerability Failure that Cause Regimen Switching. Infect. Chemother. 2015;47:231.","DOI":"10.3947\/ic.2015.47.4.231"},{"key":"12366_CR27","doi-asserted-by":"crossref","unstructured":"Reynolds SJ, et al. Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda. AIDS Lond. Engl. 2009;23:697\u2013700.","DOI":"10.1097\/QAD.0b013e3283262a78"},{"key":"12366_CR28","doi-asserted-by":"publisher","first-page":"e113813","DOI":"10.1371\/journal.pone.0113813","volume":"9","author":"K Bonner","year":"2014","unstructured":"Bonner K, et al. Expanding Access to HIV Viral Load Testing: A Systematic Review of RNA Stability in EDTA Tubes and PPT beyond Current Time and Temperature Thresholds. PLoS ONE. 2014;9:e113813.","journal-title":"PLoS ONE"},{"key":"12366_CR29","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1186\/s12889-018-5964-x","volume":"18","author":"E Nasuuna","year":"2018","unstructured":"Nasuuna E, et al. Low HIV viral suppression rates following the intensive adherence counseling (IAC) program for children and adolescents with viral failure in public health facilities in Uganda. BMC Public Health. 2018;18:1048.","journal-title":"BMC Public Health"},{"key":"12366_CR30","doi-asserted-by":"publisher","first-page":"e25542","DOI":"10.1002\/jia2.25542","volume":"23","author":"MP Fox","year":"2020","unstructured":"Fox MP, et al. Delays in repeat HIV viral load testing for those with elevated viral loads: a national perspective from South Africa. J. Int. AIDS Soc. 2020;23:e25542.","journal-title":"J. Int. AIDS Soc."},{"key":"12366_CR31","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1001\/jama.286.20.2560","volume":"286","author":"AN Phillips","year":"2001","unstructured":"Phillips AN. HIV Viral Load Response to Antiretroviral Therapy According to the Baseline CD4 Cell Count and Viral Load. JAMA. 2001;286:2560.","journal-title":"JAMA"},{"key":"12366_CR32","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1001\/jama.283.2.229","volume":"283","author":"DV Havlir","year":"2000","unstructured":"Havlir DV, et al. Drug Susceptibility in HIV Infection After Viral Rebound in Patients Receiving Indinavir-Containing Regimens. JAMA. 2000;283:229\u201334.","journal-title":"JAMA"},{"key":"12366_CR33","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.jhep.2005.05.037","volume":"43","author":"SK Fung","year":"2005","unstructured":"Fung SK, et al. Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J. Hepatol. 2005;43:937\u201343.","journal-title":"J. Hepatol."},{"key":"12366_CR34","doi-asserted-by":"crossref","unstructured":"Pannus P, et al. Rapid viral rebound after analytical treatment interruption in patients with very small HIV reservoir and minimal on-going viral transcription. J. Int. AIDS Soc. 2020;23.","DOI":"10.1002\/jia2.25453"},{"key":"12366_CR35","doi-asserted-by":"publisher","unstructured":"Grabowski MK, et al. Prevalence and predictors of persistent HIV viremia and viral rebound following universal test and treat: a population-based study. J. Infect. Dis. 2021. https:\/\/doi.org\/10.1093\/infdis\/jiab021.","DOI":"10.1093\/infdis\/jiab021"},{"key":"12366_CR36","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.chom.2019.08.003","volume":"26","author":"M-A De Scheerder","year":"2019","unstructured":"De Scheerder M-A, et al. HIV Rebound Is Predominantly Fueled by Genetically Identical Viral Expansions from Diverse Reservoirs. Cell Host Microbe. 2019;26:347\u2013358.e7.","journal-title":"Cell Host Microbe"},{"key":"12366_CR37","doi-asserted-by":"publisher","first-page":"S238","DOI":"10.1086\/651497","volume":"50","author":"AA Howard","year":"2010","unstructured":"Howard AA, El-Sadr WM. Integration of Tuberculosis and HIV Services in Sub-Saharan Africa: Lessons Learned. Clin. Infect. Dis. 2010;50:S238\u201344.","journal-title":"Clin. Infect. Dis."},{"key":"12366_CR38","doi-asserted-by":"publisher","first-page":"155","DOI":"10.5001\/omj.2011.38","volume":"26","author":"B Jimmy","year":"2011","unstructured":"Jimmy B, Jose J. Patient Medication Adherence: Measures in Daily Practice. Oman Med. J. 2011;26:155.","journal-title":"Oman Med. J."},{"key":"12366_CR39","doi-asserted-by":"crossref","unstructured":"Group, B. M. J. P. Declaration of Helsinki (1964). BMJ 313, 1448\u20131449 (1996).","DOI":"10.1136\/bmj.313.7070.1448a"},{"key":"12366_CR40","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.ijsu.2014.07.013","volume":"12","author":"E von Elm","year":"2014","unstructured":"von Elm E, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting observational studies. Int. J. Surg. 2014;12:1495\u20139.","journal-title":"Int. J. Surg."},{"key":"12366_CR41","unstructured":"Joint United Nations Programme on HIV\/AIDS (UNAIDS). 90-90-90 An ambitious treatment target to help end the AIDS epidemic. (2014)."},{"key":"12366_CR42","unstructured":"UNAIDS. Not there yet on viral suppression https:\/\/www.unaids.org\/en\/resources\/presscentre\/featurestories\/2019\/march\/20190304_gow_viral_load (2020)."},{"key":"12366_CR43","unstructured":"UNAIDS Uganda. Uganda Profile https:\/\/www.unaids.org\/en\/regionscountries\/countries\/uganda (2018)."},{"key":"12366_CR44","unstructured":"Central Public Health Laboratories (CPHL). Uganda Viral Load Dashboard. https:\/\/vldash.cphluganda.org\/ (2019)."},{"key":"12366_CR45","doi-asserted-by":"crossref","unstructured":"Tanner Z, et al. Predictors of viral suppression and rebound among HIV-positive men who have sex with men in a large multi-site Canadian cohort. BMC Infect. Dis. 2016;16.","DOI":"10.1186\/s12879-016-1926-z"},{"key":"12366_CR46","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12879-019-3824-7","volume":"19","author":"BH Chendi","year":"2019","unstructured":"Chendi BH, et al. Rate of viral load change and adherence of HIV adult patients treated with Efavirenz or Nevirapine antiretroviral regimens at 24 and 48\u2009weeks in Yaound\u00e9, Cameroon: a longitudinal cohort study. BMC Infect. Dis. 2019;19:194.","journal-title":"BMC Infect. Dis."},{"key":"12366_CR47","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1186\/s12879-017-2428-3","volume":"17","author":"L Bulage","year":"2017","unstructured":"Bulage L, et al. Factors Associated with Virological Non-suppression among HIV-Positive Patients on Antiretroviral Therapy in Uganda, August 2014\u2013July 2015. BMC Infect. Dis. 2017;17:326.","journal-title":"BMC Infect. Dis."}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-021-12366-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-021-12366-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-021-12366-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,18]],"date-time":"2021-12-18T00:02:46Z","timestamp":1639785766000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-021-12366-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["12366"],"URL":"https:\/\/doi.org\/10.1186\/s12889-021-12366-4","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"9 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None to declare","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2294"}}